课题基金 / 基金详情

Quantitative High-Throughput Screen for Inhibitors of Human alpha-Galactosidase

Quantitative High-Throughput Screen for Inhibitors of Human alpha-Galactosidase
人 α-半乳糖苷酶抑制剂的定量高通量筛选
批准号：
9205725
负责人：
Noel Southall
金额：
$5.7万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/9205725
关键词：
QuantitativeThroughputScreenInhibitorsHuman

项目摘要

项目成果

Noel Southall的其他基金

相似基金

相关文献

中文摘要
翻译
在此期间，NCGC与NIH和校外研究人员建立并维持了180多项积极合作，促进了整个人类疾病范围内的药物发现工作。这些努力已经导致了100多个高通量筛选和近60个药物化学活动，为我们的合作者和一般研究界提供了丰富的出版物和有前途的小分子线索。此外，NCGC还承担了一些信息学方面的挑战，以便更好地利用现有的药物和疾病目标信息，并向公众提供易于获得的资源，进一步促进人类疾病新疗法的发展。
英文摘要
During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification of substances that change alternative pre-mRNA splicing of the serotonin 2C receptor
Inhibitors of Cell Surface uPA Generation
Malaria Phosphatase Inhibitors Identified as a Potential New Malaria Treatment
Development of small molecule agonists of the parathyroid hormone receptor type-1 (PTHR1) as potential new therapeutics for the treatment of osteoporosis
海外基金